AMSIGLAT Trademark

Trademark Overview

On Monday, January 11, 2016, a trademark application was filed for AMSIGLAT with the United States Patent and Trademark Office. The USPTO has given the AMSIGLAT trademark a serial number of 86871312. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 5, 2019. This trademark is owned by Pfizer Inc.. The AMSIGLAT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use
amsiglat

General Information

Serial Number86871312
Word MarkAMSIGLAT
Filing DateMonday, January 11, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 5, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 10, 2016

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, January 16, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, August 5, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 5, 2019ABANDONMENT - NO USE STATEMENT FILED
Saturday, January 12, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 11, 2019EXTENSION 5 GRANTED
Wednesday, December 26, 2018EXTENSION 5 FILED
Friday, January 11, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, December 26, 2018TEAS EXTENSION RECEIVED
Wednesday, June 13, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 11, 2018EXTENSION 4 GRANTED
Monday, June 11, 2018EXTENSION 4 FILED
Monday, June 11, 2018TEAS EXTENSION RECEIVED
Friday, June 1, 2018ASSIGNED TO EXAMINER
Wednesday, December 13, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 11, 2017EXTENSION 3 GRANTED
Monday, December 11, 2017EXTENSION 3 FILED
Monday, December 11, 2017TEAS EXTENSION RECEIVED
Tuesday, June 13, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 9, 2017EXTENSION 2 GRANTED
Friday, June 9, 2017EXTENSION 2 FILED
Friday, June 9, 2017TEAS EXTENSION RECEIVED
Wednesday, November 30, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 28, 2016EXTENSION 1 GRANTED
Monday, November 28, 2016EXTENSION 1 FILED
Monday, November 28, 2016TEAS EXTENSION RECEIVED
Tuesday, July 5, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 10, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 10, 2016PUBLISHED FOR OPPOSITION
Wednesday, April 20, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 5, 2016LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, April 5, 2016ASSIGNED TO LIE
Friday, April 1, 2016ASSIGNED TO LIE
Monday, March 14, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, March 14, 2016EXAMINER'S AMENDMENT ENTERED
Monday, March 14, 2016NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, March 14, 2016EXAMINERS AMENDMENT E-MAILED
Monday, March 14, 2016EXAMINERS AMENDMENT -WRITTEN
Tuesday, March 8, 2016ASSIGNED TO EXAMINER
Saturday, January 16, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, January 14, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

amsiglat preparations pharmaceutical dysfunction treatment cancer diabetes sexual pain disorders diseases